Posted by Michael Wonder on 06 Dec 2022
Vistagen receives FDA fast track designation for development of PH10 to treat major depressive disorder
6 December 2022 - Vistagen today announced the US FDA has granted fast track designation for the development of PH10, one of the Company’s investigational nasal sprays, for the treatment of major depressive disorder.
The FDA’s decision is informed by the results of Vistagen’s non-clinical studies and three prior clinical studies of PH10, including a Phase 2A clinical study in major depressive disorder.
